Loading
Life sciences · Journal article
Cancers · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Gastric cancer remains a leading cause of cancer-related death, and its malignant behavior is driven in large part by dysregulated post-translational modifications (PTMs). Yet the prevailing tendency to study individual modifications in isolation has obscured a defining feature of PTM biology: modifications frequently interact, competing for the same residue or cooperating across residues to form regulatory switches that dictate protein fate. This review synthesizes the PTM crosstalk framework in gastric cancer around three principal axes—phosphorylation–ubiquitination relays, SUMOylation–ubiquitination interplay, and metabolic coupling through lactylation—and traces how these axes translate into the hallmarks of proliferation, metastasis, therapeutic resistance, and immune evasion. The framework is further extended to colorectal cancer to separate shared regulatory principles from cancer-specific switches. Central to this account is the proposition that oncogenic output is governed not by any single modification but by the balance among competing and cooperating marks, and that the switch enzymes maintaining this balance constitute the most informative therapeutic targets. Translating this view into therapy will require selective degraders and inhibitors, crosstalk-aware biomarkers, and systematic multi-omics maps of the modification network.